Kelly Brady
Vermögen: 42 614 $ am 31.08.2026
Vermögen: 42 614 $ am 31.08.2026
Kelly M.
Brady is currently Chief Operating Officer & Executive Vice President at Seres Therapeutics, Inc. since 2026.
Former roles include Senior Director at Akebia Therapeutics, Inc. and Member-Operations Team at Osiris Therapeutics, Inc. Education includes graduate studies at The Johns Hopkins University and undergraduate studies at Lafayette College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.08.2026 | 8’679 ( 0.09% ) | 42 614 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SERES THERAPEUTICS, INC. | Geschäftsführer | 02.03.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| OSIRIS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc. BiotechnologyHealth Technology Researches and develops therapeutic products for the regeneration of human connective tissues | Health Technology |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lafayette College
Lafayette College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Seres Therapeutics, Inc.
Seres Therapeutics, Inc. BiotechnologyHealth Technology Develops novel treatments for diseases related to the human microbiome | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen